In this study of 5,000 women, more women who received Paclitaxel once a week were likely to be alive and free of breast cancer five years after being diagnosed compared to women who received Paclitaxel every three weeks OR women who received Docetaxel (either weekly or every three weeks).

CCC Diagnostics has obtained expanded health care coverage for the DirectHit Panel for Breast Cancer. DirectHit™ provides information about the tumor that may be used its to prescribe the most effective anticancer drug treatment.